Iambic Therapeutics, Inc. Common Stock（IAM）价格预测IAMIambic Therapeutics, Inc. Common Stock

Iambic Therapeutics, Inc. is not a good buy right now due to a significant 5-day price drop of 40.11% and a year-to-date decline of 10.88%. The stock has no earnings (P/E ratio of 0) and is trading at a high price-to-sales ratio of 38.1, indicating it may be overvalued. The lack of positive insider or hedge fund activity further suggests a lack of confidence in the stock's future performance.

Iambic Therapeutics, Inc. Common Stock (IAM) last closed at $14.7799997, gaining +5.57%. These facts feed the 1-day and 1-week IAM price prediction above.